BaseLaunch funds four healthcare ventures
BaseLaunch supports carefully selected ventures in two phases. After an intense pressure test period, four projects were selected for Phase II of our second year. They now have the opportunity to further advance their breakthrough healthcare innovation and secure further investment.
The four healthcare ventures Anaveon, Pattern Biosciences, Synendos Therapeutics and a biotech in stealth mode receive funding of up to 250,000 Swiss francs as well as further support from BaseLaunch and its partners. Additionally, these projects have free-of-charge access to BaseLaunch’s co-working space and fully equipped shared laboratory in the Switzerland Innovation Park Basel Area in Allschwil.
This package allows the teams to focus on what truly matters: advancing and de-risking their science and further developing their ventures.
Applications for the BaseLaunch accelerator 2019 are now open
Further, BaseLaunch opens the next round of its accelerator program. The initiative, managed by BaselArea.swiss, is looking for people and projects with breakthrough healthcare innovations mainly in the field of therapeutics. However, applications are also open for game-changing innovation in diagnostics, medtech or related fields.
During Phase I, the selected projects develop their cases in Basel while having access to up to 10,000 Swiss francs each for consultancy and other services.
Phase II lasts at least twelve months, with each project receiving funding of up to 250,000 Swiss francs for further developing their venture.
Share this article
You might also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.Read More